VIGAFYDE: payments to doctors
Payments that named VIGAFYDE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Upsher-smith Laboratories LLC?
Upsher-smith Laboratories LLC reported the most payments naming VIGAFYDE. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $12K
- Providers
- 284
- Transactions
- 440
- Average per transaction
- $28
The per-transaction average — $28 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 284 providers the average total is $43, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Upsher-smith Laboratories LLC | $12,299 | 100.0% |
Other products from Upsher-smith Laboratories LLC
The company that reported the most payments naming VIGAFYDE also reports against these.
- TOSYMRA$487,743
- ZEMBRACE SYMTOUCH$420,937
- Tosymra Sumatriptan Nasal Spray$251,851
- QUDEXY XR Topiramate Extended Release Capsules$234,466
- Zembrace SymTouch Sumatriptan Injection$220,738
- TOPIRAMATE Extended Release Capsules$26,052
- TORPENZ$20,976
- QUDEXY$20,782
- VIGADRONE$17,492
- VIGADRONE (vigabatrin) for Oral Solution$3,589